In patients with influenza-related myocarditis, prompt diagnosis and treatment are important. Intravenous zanamivir can be an alternative to oral oseltamivir, especially in severe cases and when drug intestinal malabsorption is suspected or proven.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935647 | PMC |
| http://dx.doi.org/10.1002/ccr3.2499 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Successful Treatment of Complicated Influenza A(H3N2) Virus Infection and Rhabdomyolysis with Compassionate Use of IV Zanamivir.
Pharmaceuticals (Basel)
January 2023
Vaccine Safety Initiative, 10437 Berlin, Germany.
In 2019, EMA licensed intravenous (IV) zanamivir for severe influenza virus infection in children over 6 months as well as adults. Prior to that, it was possible via a compassionate use program. We present successful compassionate use of IV zanamivir in a 14-year-old female with severe influenza A(H3N2) and multi-organ failure, who had failed oral oseltamivir.
View Article and Find Full Text PDFLessons from resistance analysis in clinical trials of IV zanamivir.
Virus Res
February 2023
GlaxoSmithKline, Boston, United States.
Influenza infection causes substantial morbidity and mortality during seasonal epidemics and pandemics. Antivirals, including neuraminidase inhibitors, play an important role in the treatment of severely ill patients infected with influenza. Resistance is a key factor that can affect the efficacy of neuraminidase inhibitors (NAIs).
View Article and Find Full Text PDFThe Hospital Recovery Scale: A clinically useful endpoint in patients hospitalized with influenza.
Contemp Clin Trials
December 2022
Medical Department, Janssen Research & Development, Titusville, NJ, USA.
Background: Currently, no single best primary endpoint exists for measuring the efficacy of treatments in seriously ill patients with respiratory infections, such as influenza, who require hospitalization. The Hospital Recovery Scale is an ordinal endpoint used to evaluate treatment outcomes in clinical studies of hospitalized patients infected with influenza.
Methods: To determine whether Hospital Recovery Scale outcomes correspond to those for other clinical endpoints in patients hospitalized due to influenza, data from the phase 3 randomized, double-blind ZORO clinical trial (NCT01231620) were analyzed.
Zanamivir aqueous solution in severe influenza: A global Compassionate Use Program, 2009-2019.
Influenza Other Respir Viruses
May 2022
Global Health R&D, GSK, Brentford, Middlesex, UK.
Background: Zanamivir is a neuraminidase inhibitor effective against influenza A and B viruses. In 2009, GlaxoSmithKline (GSK) began clinical development of intravenous (IV) zanamivir and initiated a global Compassionate Use Program (CUP) in response to the evolving H1N1 global pandemic. The goal of the CUP was to provide zanamivir to critically ill patients with limited treatment options.
View Article and Find Full Text PDFAssociation between anaphylaxis and anti-influenza drug use: An analysis of the Japanese Adverse Drug Event Report database.
Drug Discov Ther
December 2021
Department of Practical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan.
We aimed to investigate the association between anaphylaxis and anti-influenza drug use using the Japanese Adverse Drug Event Report (JADER) database, a national spontaneous reporting database in Japan. We surveyed registered cases from the JADER database between April 2004 and November 2019. The target drugs were five anti-influenza drugs, namely oseltamivir, zanamivir, peramivir, laninamivir, and baloxavir.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!